Memorial Sloan Kettering Cancer Center Advanced Therapeutics for Brain Metastasis 2026
$10.00
Explore multimodal treatment for brain metastases through Memorial Sloan Kettering lectures and case discussions. The program covers systemic therapies, radiosurgery, brachytherapy, surgery, leptomeningeal disease, CNS toxicity, and imaging, alongside research frontiers and a multidisciplinary tumor board focused on difficult treatment decisions.
Delivery Information: This Product is shared via google drive download link. Please use your correct Gmail address at checkout.
Please note: there are no CME points or certificate associated with this course.
Samples for Courses Can be found here: Free Samples Here!
Advanced Therapeutics for Brain Metastasis examines how systemic treatment, radiation, and surgery fit together in neuro-oncology. Directed by Nelson Moss, the September 9, 2026 Memorial Sloan Kettering virtual conference combines disease-specific updates with discussion of treatment sequencing and unresolved clinical questions. Sessions cover breast, lung, and melanoma brain metastases; stereotactic radiosurgery; brachytherapy; laser interstitial thermal therapy; and leptomeningeal disease. Further presentations address treatment-related CNS toxicity, advanced imaging, biomarkers, the metastatic microenvironment, and trial design. A multidisciplinary tumor board connects these subjects to clinical cases, making the program relevant to oncologists, neurosurgeons, radiation specialists, neuroradiologists, and researchers.
Learning Objectives
- Describe the current multimodal landscape of brain metastasis treatment.
- Identify key clinical controversies in brain metastasis management.
- Discuss barriers to improved treatments and potential research strategies (e.g. limited CNS activity of systemic anti-cancer treatments, side effects of local treatments, limited survival, and unclear endpoints).
The original virtual conference listed up to 7.50 AMA credits. Those credits, conference registration, and provider-platform access are not included with store files. The agenda describes the educational program rather than independently confirming every recording.
Topics and Speakers
| Time | Topic | Speaker(s) |
| 8:10 – 8:30 am | Brain Metastases: From Population Health to Precision Medicine | Matthias Preusser, MD |
| 8:30 – 8:35 am | Patient Perspectives on Living with Brain Metastases | Julia Maues, MA |
| 8:35 – 8:40 am | Q&A and Panel Discussion | |
| 8:40 – 8:55 am | Breast Cancer: Navigating the ADC Era — Efficacy, Toxicity, and Sequencing | Carey K. Anders, MD |
| 8:55 – 9:10 am | Melanoma Brain Metastases: Systemic Therapy Update | Hussein Tawbi, MD, PhD |
| 9:10 – 9:25 am | Thoracic Oncology Update | Gregory Riely, MD |
| 9:25 – 9:35 am | Q&A and Panel Discussion | Priya Kumthekar, MD (Moderator) |
| 9:45 – 10:00 am | Modern SRS: Fractionation Strategies and Combination with Systemic Therapy | Michelle Kim, MD |
| 10:00 – 10:15 am | Cs-131 Brachytherapy for Recurrent Brain Metastases | Nelson Moss, MD; Brandon Imber, MD |
| 10:15 – 10:30 am | Laser Interstitial Thermal Therapy: Expanding Indications and Long-term Outcomes | Veronica Chiang, MD |
| 10:30 – 10:45 am | Surgical Decision-Making in the Age of Effective Systemic Therapy | Gelareh Zadeh, MD, PhD |
| 10:45 – 10:55 am | Q&A and Panel Discussion | |
| 11:00 – 11:20 am | Biology, Imaging, and Pathophysiology of Leptomeningeal Disease | Michael Weller, MD |
| 11:20 – 11:40 am | CSF Liquid Biopsy and Biomarkers for Leptomeningeal Disease | Chetan B Bettegowda, MD, PhD |
| 11:40 – 11:50 am | Q&A and Panel Discussion | Jessica Wilcox, MD (Moderator) |
| 12:00 – 12:20 pm | Upfront Brain-Directed Therapy vs Systemic-First Approaches |
Brain-Directed: Luke R. G. Pike, MD, DPhil
Systemic-First: Manmeet Singh Ahluwalia, MD |
| 12:20 – 12:35 pm | ADC-Associated CNS Toxicity: Mechanism, Recognition, and Management | Yao Yu, MD |
| 12:35 – 12:50 pm | Where Radiation Fits in the Era of Potent Systemic Therapy | Ayal Aizer, MD |
| 12:50 – 1:00 pm | Q&A and Panel Discussion | |
| 1:50 – 2:05 pm | Breast Cancer Controversies in the ADC Era | Paolo Tarantino, MD |
| 2:05 – 2:20 pm | Immunotherapy-Related CNS Toxicity: Real-World Data and Management | Isabella C Glitza Oliva, MD, PhD, MS |
| 2:20 – 2:35 pm | Advanced Imaging: Amino Acid PET, AI, and Radiomics for Distinguishing Progression from Treatment Effect | Norbert Galldiks, MD |
| 2:35 – 2:45 pm | Q&A and Panel Discussion | Joshua A Budhu, MD, MPH (Moderator) |
| 2:55 – 3:15 pm | Microenvironment and Metastatic Niche: New Therapeutic Targets | Josh Neman, PhD |
| 3:15 – 3:30 pm | Brain Metastasis Microenvironment | Nathalie Agar, PhD |
| 3:30 – 3:50 pm | FDA Perspectives on Brain Metastasis Clinical Trials: Endpoints, Design, and Regulatory Considerations | Tatiana Prowell, MD |
| 3:50 – 4:05 pm | Q&A and Panel Discussion | Minesh Mehta, MD (Moderator) |
| 4:05 – 5:00 pm | Multidisciplinary Tumor Board | Andrew D Seidman, MD; Brandon Imber, MD; Gregory Riely, MD; Robert Young, MD |
Course Director
Nelson Moss, MD
Co-Director, Multidisciplinary Brain Metastasis Program
Associate Attending, Department of Neurosurgery
Memorial Sloan Kettering Cancer Center
Featured Faculty
- Nathalie Agar, PhD
- Manmeet Singh Ahluwalia, MD
- Ayal Aizer, MD, MHS
- Carey K. Anders, MD
- Chetan Bettegowda, MD, PhD
- Veronica Chiang, MD
- Norbert Galldiks, MD
- Michelle M. Kim, MD
- Priya U. Kumthekar, MD
- Julia Maués, MA
- Minesh Mehta, MD
- Josh Neman-Ebrahim, PhD
- Isabella C. Glitza Oliva, MD, PhD, MS
- Matthias Preusser, MD
- Tatiana Michelle Prowell, MD
- Paolo Tarantino, MD
- Hussein A. Tawbi, MD, PhD
- Michael Weller, MD
- Gelareh Zadeh, MD, PhD
Additional MSK Faculty
- Joshua A. Budhu, MD, MS, MPH
- Brandon Imber, MD, MA
- Luke R. G. Pike, MD, DPhil
- Gregory J. Riely, MD, PhD
- Andrew D. Seidman, MD
- Viviane Tabar, MD
- Jessica A. Wilcox, MD
- Robert J. Young, MD
- Yao Yu, MD
Related products
General Surgery
General Surgery
Cardiology
Hematology / Oncology
General Surgery